1. A retrospective analysis demonstrated that prostate-specific antigen (PSA) screening has overall declined in popularity in recent years. 2. Health ...
1. 5-year progression-free status was greatest in group 3 (triple therapy) and lowest in group 1 (pelvic bed radiotherapy alone). ...
1. Abiraterone acetate plus standard treatment significantly increased length of metastasis-free survival in men with non-metastatic prostate cancer compared to ...
1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade ...
1. 3-year event-free survival rates were significantly greater in the 18F-fluciclovine-PET group compared to conventional imaging. 2. Adverse reactions and ...
1. Radiolabeled Lutetium-177 offered greater PSA response versus current standard of care, cabazitaxel. 2. Fewer grade 3-4 adverse events occurred ...
1. Relugolix was shown to significantly decrease testosterone levels for a sustained period of time in male patients with advanced ...
There is a need for focal therapies for low to intermediate-risk prostate cancers, as whole-gland therapies have many complications without ...
